Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Fosun Pharma: Controlling subsidiary's drug approved for clinical trials
People’s Financial News, March 16 — Fosun Pharma (600196) announced on March 16 that its controlling subsidiary, Shanghai Fosun Hanlin Biotech Co., Ltd., and its subsidiaries (collectively “Fosun Hanlin”) have received approval from the National Medical Products Administration to conduct clinical trials for HLX07 (a recombinant anti-EGFR humanized monoclonal antibody injection) combined with SuliLi injection (brand name in China: Hanshuang®) and chemotherapy for the treatment of advanced squamous non-small cell lung cancer (sqNSCLC). Fosun Hanlin plans to initiate relevant clinical research on this treatment regimen in China once conditions are met. As of the announcement date, no similar combination therapy has been approved for market release worldwide.